Nuclera & Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development

Nuclera recently announced a collaboration with Cytiva focused on accelerating the production, purification, and characterization of proteins required for drug research and development, enabled through the combination of Nuclera’s eProtein Discovery System with Cytiva’s Biacore surface plasmon resonance (SPR) technology.

Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera’s eProtein Discovery System was used to produce Bruton’s Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva’s Biacore SPR system.

Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, said “Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery’s ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery’s capability to streamline protein production workflows with Cytiva’s Biacore protein characterization systems open a whole new avenue for accelerating drug development.”

Anna Moberg, Senior Manager and Project Manager, Cytiva, added “The ability of Nuclera’s eProtein Discovery to accelerate protein production and purification complements Cytiva’s Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.”

For more information about Nuclera’s eProtein Discovery System, visit https://www.nuclera.com/system/

Nuclera’s mission is to better human health by enabling scientists to easily access the proteins they need for drug discovery research. The Company’s eProtein Discovery™ benchtop System accelerates protein expression and purification optimization in research labs.

Applying digital microfluidics alongside in situ protein detection assays and cell-free protein synthesis, eProtein Discovery enables rapid, scalable access to high-quality proteins, supporting both cell-free and cell-based expression methods. The System significantly reduces time and cost of these processes by automating construct screening, protein scale-up, and producing purified proteins in under 48 hours for downstream functional testing. The System accelerates workflows, achieving results in days rather than the months required by traditional cell-based methods. Founded in 2013, Nuclera’s offices are located in Cambridge (UK) and Boston (US). For more information please visit: www.nuclera.com

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15,000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at cytiva.com.